RxDoctor Payments Data

Justin Tuot

Family Medicine · Banning, CANPI 1770080731

Payments from drug & device makers

$253in general payments, 2019–2025

Across 12 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$50
  • Novo Nordisk$45
  • Amgen$43
  • GSK$42
  • Lilly USA, LLC$23
  • Bayer$17
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$50
Novo Nordisk2$45
Amgen2$43
GSK2$42
Lilly USA, LLC1$23
Bayer1$17
Boehringer Ingelheim1$17
AstraZeneca1$16

How this compares

$253 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$18,002
Medicare patients
74
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$146,599
OzempicSemaglutide37$38,321
TrulicityDulaglutide19$37,913
JanuviaSitagliptin Phosphate23$32,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,300
RybelsusSemaglutide23$31,849
MounjaroTirzepatide29$31,579
JardianceEmpagliflozin20$24,144
MyrbetriqMirabegron20$18,699
LinzessLinaclotide32$18,673
FarxigaDapagliflozin Propanediol13$16,313
XareltoRivaroxaban13$12,999
Breo ElliptaFluticasone/Vilanterol18$11,259
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$7,109
Humalog Kwikpen U-100Insulin Lispro22$5,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$50$148,597185 claims
Novo NordiskOzempic, Rybelsus$45$70,17060 claims
Lilly USA, LLCTrulicity, Mounjaro$23$69,49248 claims
GSKTrelegy Ellipta, Breo Ellipta$42$43,55960 claims
Boehringer IngelheimJardiance$17$24,14420 claims
AstraZenecaFarxiga$16$16,31313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 10,533 family medicine providers in California.

Other family medicine in Banning

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →